Neurotar Ltd, a Helsinki (Finland) based CRO, pioneers commercial services based on in vivo two-photon imaging. These services combine the relevance of imaging within a living organism with a nanometer scale resolution. The company’s competitive advantage is based on its access to the state-of-the-art equipment and more than ten years of in vivo two-photon imaging expertise.
Neurotar focuses primarily on CNS (stroke, epilepsy, meningitis, autism, spinal cord injury, TBI, schizophrenia, neurodegeneration: AD, ALS, MS and HD) and skin (dermatology and cosmetology). Other applications include immunology, oncology, drug delivery (across BBB and PK/PD), inflammation, and 3D cultures.
Neurotar prides itself on offering customized solutions to specific customer needs, which result in significant time and money savings at target validation, lead & candidate selection and early clinical (skin only) stages of drug discovery and development.
